Endo to pay $10 million after settlement in opioid casesChristian Fernsby ▼ | September 5, 2019
Endo International announced that its subsidiaries Endo Pharmaceuticals Inc., Endo Health Solutions Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. have executed a definitive Settlement Agreement and Release with the County of Cuyahoga, Ohio, the County of Summit, Ohio and certain related persons.
Canada Endo Pharmaceuticals
Topics: Endo settlement opioid
The Settlement Agreement fully resolves all claims that were or could have been asserted by the two plaintiff counties against the Endo Entities in the Track 1 Cases, including claims arising from or otherwise relating to the manufacturing, marketing, distribution, supply, sale, prescribing, use and/or abuse of branded and generic opioid medications.
Under the Settlement Agreement, Endo will pay a total sum of $10 million and will provide up to $1 million of its Vasostrict and Adrenalin products free of charge, to be initially allocated by and between the two plaintiff counties as follows: Cuyahoga County will receive $6.2 million in cash and up to $620,000 of Vasostrict and/or Adrenalin; and Summit County will receive $3.8 million in cash and up to $380,000 of Vasostrict and/or Adrenalin.
The two plaintiff counties may further apportion and use the foregoing amounts in their sole discretion.
Further, in the event of a comprehensive resolution of government-related opioid claims, the company has agreed that the two plaintiff counties will receive the value they would have received under such resolution less the total value of the Settlement Agreement.
The Settlement Agreement includes no admission of wrongdoing, fault or liability of any kind by the Endo Entities and avoids litigation risk and associated costs.
It is important to note that the value of the Settlement Agreement should not be extrapolated to any other opioid-related cases or claims. ■